1. 89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
- Author
-
Verhoeff, S.R., Donk, P.P. van de, Aarntzen, E.H.J.G., Oosting, S.F., Brouwers, A.H., Miedema, I.H.C., Voortman, J., Oordt, W.C.M.V. van, Boellaard, R., Vriens, D., Slingerland, M., Hermsen, R., Engen-van Grunsven van, Heskamp, S., Herpen, C.M.L. van, Internal medicine, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Amsterdam Neuroscience - Brain Imaging, Radiology and nuclear medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
- Subjects
PD-L1 ,immune checkpoint inhibitors ,All institutes and research themes of the Radboud University Medical Center ,durvalumab ,immuno-PET ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Radiology, Nuclear Medicine and imaging ,head and neck cancer ,Clinical Investigation ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,Key Words ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed (89)Zr-DFO-durvalumab (anti–PD-L1 [programmed death ligand 1]) PET/CT in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) before monotherapy durvalumab treatment. The primary aims were to assess safety and feasibility of (89)Zr-DFO-durvalumab PET imaging and predict disease control rate during durvalumab treatment. Secondary aims were to correlate (89)Zr-DFO-durvalumab uptake to tumor PD-L1 expression, (18)F-FDG uptake, and treatment response of individual lesions. Methods: In this prospective multicenter phase I–II study (NCT03829007), patients with incurable R/M SCCHN underwent baseline (18)F-FDG PET and CT or MRI. Subsequently, PD-L1 PET imaging was performed 5 d after administration of 37 MBq of (89)Zr-DFO-durvalumab. To optimize imaging conditions, dose finding was performed in the first 14 patients. For all patients (n = 33), durvalumab treatment (1,500 mg/4 wk, intravenously) was started within 1 wk after PD-L1 PET imaging and continued until disease progression or unacceptable toxicity (maximum, 24 mo). CT evaluation was assessed according to RECIST 1.1 every 8 wk. PD-L1 expression was determined by combined positive score on (archival) tumor tissue. (89)Zr-DFO-durvalumab uptake was measured in (18)F-FDG–positive lesions, primary and secondary lymphoid organs, and blood pool. Results: In total, 33 patients with locoregional recurrent (n = 12) or metastatic SCCHN (n = 21) were enrolled. (89)Zr-DFO-durvalumab injection was safe. A dose of 10 mg of durvalumab resulted in highest tumor-to-blood ratios. After a median follow-up of 12.6 mo, overall response rate was 26%. The disease control rate at 16 wk was 48%, with a mean duration of 7.8 mo (range, 1.7–21.1). On a patient level, (89)Zr-DFO-durvalumab SUV(peak) or tumor-to-blood ratio could not predict treatment response (hazard ratio, 1.5 [95% CI, 0.5–3.9; P = 0.45] and 1.3 [95% CI, 0.5–3.3; P = 0.60], respectively). Also, on a lesion level, (89)Zr-DFO-durvalumab SUV(peak) showed no substantial correlation to treatment response (Spearman ρ, 0.45; P = 0.051). Lesional (89)Zr-DFO-durvalumab uptake did not correlate to PD-L1 combined positive score but did correlate to (18)F-FDG SUV(peak) (Spearman ρ, 0.391; P = 0.005). Conclusion: PINCH is the first, to our knowledge, PD-L1 PET/CT study in patients with R/M SCCHN and has shown the feasibility and safety of (89)Zr-DFO-durvalumab PET/CT in a multicenter trial. (89)Zr-DFO-durvalumab uptake did not correlate to durvalumab treatment response.
- Published
- 2022
- Full Text
- View/download PDF